Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L04AC

Ilumetri(tildrakizumab)

Psoriasis

Marketing Authorisation Holder: Almirall, S.A.

EMA Authorisation: 17/09/2018

INN: tildrakizumab

Indication

Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ilumetri — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.